Cost‐effectiveness analysis of first‐line treatments for advanced epidermal growth factor receptor‐mutant non‐small cell lung cancer patients

Cost‐effectiveness analysis of first‐line treatments for advanced epidermal growth factor receptor‐mutant non‐small cell lung cancer patients

Abstract Objectives Recent studies showed prolonged survival for advanced epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) patients treated with both monotherapies and combined therapies. However, high costs limit clinical applications. Thus, we conducted this cost‐e...

Full description

Bibliographic Details
Main Authors:	Wen‐Qian Li, Ling‐Yu Li, Jin Chai, Jiu‐Wei Cui
Format:	Article
Language:	English
Published:	Wiley 2021-03-01
Series:	Cancer Medicine
Subjects:	cost‐effectiveness epidermal growth factor receptor first‐line therapy non‐small cell lung cancer
Online Access:	https://doi.org/10.1002/cam4.3733

Similar Items

Immunotherapy in Epidermal Growth Factor Receptor-mutant  Non-small Cell Lung Cancer
by: Xin WANG, et al.
Published: (2019-08-01)

Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
by: Sviatoslav Chekhun, et al.
Published: (2023-12-01)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
by: Vanita Noronha, et al.
Published: (2020-01-01)

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
by: William J. Kelly, et al.
Published: (2018-07-01)

Prognostic value of epidermal growth factor receptor expression in operable non-small cell lung carcinoma
by: Seyhan Ekrem, et al.
Published: (2010-10-01)

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
by: Shouzheng Wang, et al.
Published: (2021-10-01)

Progress and prospect of epidermal growth factor receptor tyrosine kinase inhibitor in treatment of non-small cell lung cancer
by: JIANG Hanshui, et al.
Published: (2022-12-01)

Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients
by: Lanlan Liu, et al.
Published: (2021-12-01)

Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population
by: Gaye Güler Tezel, et al.
Published: (2017-12-01)

Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study
by: Jingwen Wei, et al.
Published: (2022-10-01)

Protein expression, gene amplification, epidermal growth factor receptor mutations and lung carcinoma
by: Panjković Milana, et al.
Published: (2014-01-01)

Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma
by: Jinn-Li Wang, et al.
Published: (2018-06-01)

T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors
by: Vinodini Merinda, et al.
Published: (2020-01-01)

Expression of Epidermal Growth Factor Receptor and the association with Demographic and Prognostic Factors in Patients with Non-small Cell Lung Cancer
by: Reza Basiri, et al.
Published: (2015-06-01)

Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor ()-Mutant Lung Adenocarcinoma
by: Eunhyang Park, et al.
Published: (2015-09-01)

A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer
by: Song Hu, et al.
Published: (2024-04-01)

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
by: Guiyuan Xiang, et al.
Published: (2023-08-01)

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
by: Zhiwei Zheng, et al.
Published: (2022-09-01)

Epidermal growth factor receptor gene mutations in non-small-cell lung cancer cells are associated with increased radiosensitivity in vitro
by: Xie B, et al.
Published: (2018-09-01)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
by: Sojung Park, et al.
Published: (2021-01-01)

Epidermal Growth Factor Receptor Mutations and Radiotherapy  in Non-small Cell Lung Cancer
by: Xing ZHONG, et al.
Published: (2013-03-01)

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)
by: Tomoya Fukui, et al.
Published: (2022-12-01)

Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer
by: Huang HM, et al.
Published: (2022-12-01)

Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
by: Hiroshi Nokihara, et al.
Published: (2022-06-01)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
by: Tingting Lu, et al.
Published: (2023-07-01)

Comparison between cryobiopsy and forceps biopsy in detection of epidermal growth factor receptor amplification in non-small-cell lung cancer
by: Ahmed S. H. Mohamed, et al.
Published: (2020-01-01)

A rare epidermal growth factor receptor (EGFR) gene mutation in small cell lung carcinoma patients
by: Cheng-Cheng Hwang, et al.
Published: (2022-09-01)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
by: Lijuan Zhang, et al.
Published: (2021-01-01)

Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer
by: Li‐Chung Chiu, et al.
Published: (2024-03-01)

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study
by: Xiaoxu Fang, et al.
Published: (2023-09-01)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
by: Chen Chen, et al.
Published: (2020-03-01)

Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis
by: Wenqian Li, et al.
Published: (2021-03-01)

Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis
by: Marie Westwood, et al.
Published: (2014-05-01)

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01)

The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
by: Tu-Chen Liu, et al.
Published: (2016-05-01)

De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
by: Takumi Fujiwara, et al.
Published: (2020-10-01)

Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors
by: Yue-Yun Chen, et al.
Published: (2021-08-01)

The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases
by: Jianxi Zhou, et al.
Published: (2024-01-01)

Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region
by: Arafat Hussein Tfayli, et al.
Published: (2019-01-01)

Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review
by: Mousa Alali, et al.
Published: (2023-08-01)